Traditionally, expectant mothers have been excluded from clinical trials, but could this practice be doing more harm than good?
When the heart stops beating, minutes matter. With every minute that passes before a rhythm is restored, a patient's odds of survival plummet. Which is why Anne Lyerly was surprised when, one night 20 years ago, she got a phone call from a doctor who had paused in the middle of treating a patient in cardiac arrest. Lyerly was a newly minted obstetrician; the caller was an internal medicine resident who was desperately trying to resuscitate a dying patient. A pregnant dying patient. He had called because his supervisor wanted to know whether a critical cardiac drug would be safe for the woman's foetus.